We, friends & family of people with Fabry disease, and those have Fabry disease are requesting you, Shire, to resubmit your application for FDA approval to make Replagal (your drug for Fabry disease) available to United States patients. It is currently unavailable except through trials. This is such an unusual disease that medication is not abundant. We understand Genzyme’s drug Fabrazyme has experienced massive breakdowns in the production and have therefore rationed the consumers of the medication from having none available to possibly a half dose per month. Our understanding is this shortage, with rationing, will continue into 2012. This has led to patients with Fabry having declining health problems resulting in inability to work, hospitalizations, home care, nursing home admittance, and even death due to complications from symptoms of Fabry disease. Those newly diagnosed are ending up on waiting lists & not getting any relief. Please, also reconsider the IND program for aiding these current complications. Thank you, The Patients, Friends, & Family of the Fabry Community.